

Application/Control Number: 10/760,970

Page 2

Art Unit: 1623

CLMPTO

01/20/2004


DM

Claims 1-64 (Cancel)

Claims 65-77 (Original)



Art Unit: 1623

65. A pharmaceutical composition useful for the treatment of inflammatory disease or for reducing inflammation which composition comprises an inflammation reducing effective amount of a compound having the formula




wherein  $R_2$  is hydrogen, a monomeric glycoside or an oligomeric glycoside,  $R_3$  is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula  $\text{—CH}(\text{CH}_3)\text{C}(=\text{O})\text{—OCH}_2\text{O—R}_8$ ,  $R$  is a lower alkylene,  $R'$  is

selected from the group consisting of moieties having the formula




and



Art Unit: 1623


where  $X = 0$  or  $1$ ,  $Y = 0$  or  $1$ ,

$R_1$  is hydrogen or a pharmacologically active drug residue,  $R_8$  a pharmacologically active drug residue,  $R_4$ ,  $R_5$ , and  $R_6$  are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




and  $R_7$  is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

66. A pharmaceutical composition useful for the treatment of infectious disease or for reducing infection which composition comprises an infection reducing effective amount of a compound having the formula



wherein  $R_2$  is hydrogen, a monomeric glycoside or an oligomeric glycoside,  $R_3$  is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula  $-\text{CH}(\text{CH}_3)\text{C}(=\text{O})\text{OCH}_2\text{O}-R_8$ ,  $R$  is a lower alkylene,  $R'$  is


selected from the group consisting of moieties having the formula



Art Unit: 1623


where  $X = 0$  or  $1$ ,  $Y = 0$  or  $1$ ,

$R_1$  is hydrogen or a pharmacologically active drug residue,  $R_8$  a pharmacologically active drug residue,  $R_4$ ,  $R_5$ , and  $R_6$  are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




and  $R_7$  is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

67. A pharmaceutical composition useful for the treatment of glaucoma or for reducing intraocular pressure which composition comprises a therapeutically effective amount of a compound having the formula



wherein  $R_2$  is hydrogen, a monomeric glycoside or an oligomeric glycoside,  $R_3$  is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula  $-\text{CH}(\text{CH}_3)\text{C}(=\text{O})\text{OCH}_2\text{O}-R_8$ ,  $R$  is a lower alkylene,  $R'$  is


selected from the group consisting of moieties having the formula



where  $X = 0$  or  $1$ ,  $Y = 0$  or  $1$ .


Art Unit: 1623

$R_1$  is hydrogen or a pharmacologically active drug residue,  $R_8$  a pharmacologically active drug residue,  $R_4$ ,  $R_5$ , and  $R_6$  are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




and  $R_7$  is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

68.A pharmaceutical composition useful for administering therapeutic compositions ocularly for the treatment of systemic disorders, which composition comprises a therapeutically effective amount of a compound having the formula



wherein  $R_2$  is hydrogen, a monomeric glycoside or an oligomeric glycoside,  $R_3$  is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula  $\text{---CH}(\text{CH}_3)\text{C}(=\text{O})\text{---OCH}_2\text{O---R}_8$ ,  $R$  is a lower alkylene,  $R'$  is


selected from the group consisting of moieties having the formula



Art Unit: 1623


where  $X = 0$  or  $1$ ,  $Y = 0$  or  $1$ ,

$R_1$  is hydrogen or a pharmacologically active drug residue,  $R_8$  a pharmacologically active drug residue,  $R_4$ ,  $R_5$ , and  $R_6$  are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




and  $R_7$  is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

69. A compound having the formula




wherein  $R_2$  and  $R_3$  are independently hydrogen, or a glycoside having the formula




where  $n=0$  to  $8$  and  $R_9$  is an alkyl, alkylene, monocationic alkylamine or polycationic alkylamine.

Art Unit: 1623

R is a lower alkylene, R' is




where X = 0 or 1, Y = 0 or 1, R<sub>1</sub> is hydrogen or a pharmacologically active drug residue, and R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

70. The compound of Claim 69 wherein R<sub>2</sub> is hydrogen and R<sub>3</sub> is a glycoside having the formula



Art Unit: 1623

71. The compound of Claim 70 wherein  $R_3$  is a glycoside having the formula




where  $n=0$ .

72. The compound of Claim 70 wherein  $R_9$  is a monocationic alkylamine or polycationic alkylamine.

73. The compound of Claim 72 wherein the alkylamine is a quaternary amine.


74. The compound of Claim 71 having the formula





Art Unit: 1623

75. The compound of Claim 70 having the formula



76. The compound of Claim 75 wherein  $R_9$  is a monocationic alkylamine or polycationic alkylamine.

77. The compound of Claim 76 wherein the alkylamine is a quaternary amine.